Allogene Therapeutics, Inc. (ALLO) - 10-Q Summary
Business Context and Reporting Period
Company: Allogene Therapeutics, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Allogene is a clinical-stage immuno-oncology company developing genetically engineered allogeneic ("off-the-shelf") T cell product candidates for cancer and autoimmune diseases. The company focuses on three core clinical programs: ALPHA3 (cema-cel for large B-cell lymphoma), TRAVERSE (ALLO-316 for renal cell carcinoma), and RESOLUTION (ALLO-329 for autoimmune diseases).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|
| Collaboration Revenue | $4,640 | $4,640 | $0 |
| Total Operating Expenses | $51,560 | $97,652 | $122,010 |
| Net Loss | $(42,677) | $(85,284) | $(110,676) |
| Net Loss Per Share (Basic/Diluted) | $(0.13) | $(0.30) | $(0.51) |
| Cash, Cash Equivalents & Investments | $423,600 (as of June 30, 2026) | ||
| Accumulated Deficit | $(2,095,993) (as of June 30, 2026) |
Liquidity & Cash Flow:
- Operating Cash Flow: Used $44.9 million for the six months ended June 30, 2026, compared to $92.0 million in the prior year period.
- Financing Cash Flow: Provided $209.0 million, primarily driven by a public offering and ATM sales.
- Investing Cash Flow: Used $177.1 million, primarily for the purchase of investments.
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $4.6 million in collaboration revenue related to the termination of its License Agreement with Overland Therapeutics. This revenue was non-existent in the prior year periods.
- Expense Reduction: Total operating expenses decreased by approximately 20% ($24.4 million) year-over-year for the six-month period. This was driven by a $27.6 million decrease in R&D expenses (due to reduced personnel costs, severance, and development timing) and a $2.4 million decrease in impairment charges (which were present in 2025 but absent in 2026).
- Capital Raise: In April 2026, the company completed a public offering of 100.2 million shares at $2.00 per share, raising net proceeds of approximately $187.9 million. Additionally, ATM offerings generated $20.7 million in net proceeds during the six-month period.
- Leadership Change: David Chang transitioned from CEO to non-employee director effective June 30, 2026. Zachary Roberts was appointed President and CEO effective July 1, 2026.
Guidance, Outlook, and Risks
Outlook & Runway: Management expects cash, cash equivalents, and investments of $423.6 million as of June 30, 2026, to be sufficient to fund operations into the first quarter of 2029. The company anticipates continuing to incur net losses as it advances clinical programs.
Clinical Updates:
- ALPHA3 (cema-cel): Interim futility analysis of the first 24 randomized patients showed 58.3% MRD negativity in the cema-cel arm vs. 16.7% in the observation arm. The trial was amended to remove the ALLO-647 lymphodepletion arm following a Grade 5 adverse event (hepatic failure) in the prior arm. The trial now proceeds with standard fludarabine and cyclophosphamide (FC) lymphodepletion.
- TRAVERSE (ALLO-316): Phase 1b expansion cohort completed enrollment. Data showed a 25.0% overall response rate.
- RESOLUTION (ALLO-329): Phase 1 rheumatology basket study is ongoing with dose escalation.
Key Risks & Contingencies:
- Intellectual Property Litigation: Factor Bioscience has sued Cellectis (Allogene's TALEN technology licensor) alleging patent infringement. Additionally, Life Technologies Corporation (LTC) has asserted termination of licenses with Cellectis, potentially impacting Allogene's rights to TALEN technology.
- Companion Diagnostic Reliance: The ALPHA3 trial relies on the CLARITY MRD assay developed by Foresight Diagnostics (acquired by Natera). Delays in regulatory approval or commercialization of this assay could hinder cema-cel development.
- Manufacturing: The company reduced manufacturing operations in 2025. While hiring has resumed, there are risks regarding the ability to ramp up production and maintain operational readiness.
Investor Verification Checklist
- Capital Runway: Verify the $423.6 million cash position and the projected runway into Q1 2029 against current burn rates.
- IP Litigation Status: Monitor the outcome of the Factor Bioscience vs. Cellectis litigation and the LTC vs. Cellectis arbitration, as these directly impact the validity of Allogene's core TALEN technology license.
- ALPHA3 Trial Design: Confirm the enrollment progress and safety profile of the amended ALPHA3 trial using the FC lymphodepletion regimen (without ALLO-647).
- Companion Diagnostic: Track the regulatory status of the Foresight Diagnostics CLARITY MRD assay, which is critical for patient selection in the pivotal trial.
- Overland Termination: Review the terms of the terminated Overland Therapeutics agreement to ensure no hidden liabilities remain and that the $4.6 million revenue recognition is fully realized.